Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
03 Oct 23
Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
03 Oct 23
The acquisition equips Clade with preclinical cell therapy programmes, a g/d TCR discovery engine, and cell enhancement technologies…
03 Oct 23
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule
03 Oct 23
The agreement expands the companies' existing relationship, which entails collaborating on IND-enabling preclinical studies for IAMA-6
29 Sep 23
.The proceeds of the financing will support the advancement of Deka’s pipeline and drug product manufacturing as they…
28 Sep 23
The Swiss pharmaceutical firm will obtain exclusive global rights to develop, manufacture, and market the medicines by making…
28 Sep 23
Under the partnership, Pfizer will use Ginkgo's patented RNA technology to discover RNA-based drug candidates and in return,…
28 Sep 23
BigRNA is designed to accurately predict the tissue-specific regulatory mechanisms of RNA expression and predict the binding sites…